These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
    Author: Clotet B, Clumeck N, Katlama C, Nijs S, Witek J.
    Journal: J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782.
    Abstract:
    OBJECTIVES: Human immunodeficiency virus (HIV)-infected patients are frequently co-infected with hepatitis B and/or C virus (HBV/HCV). The safety of etravirine was investigated over 96 weeks in patients co-infected with HIV type-1 (HIV-1) and HBV and/or HCV in the Phase III DUET trials. DUET-1 and DUET-2 are registered with clinicaltrials.gov (NCT00254046 and NCT00255099, respectively). METHODS: Treatment-experienced, HIV-1-infected patients with documented non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance were randomized to receive either etravirine 200 mg or placebo, both twice daily plus a background regimen of darunavir/ritonavir, investigator-selected nucleoside reverse transcriptase inhibitors and optional enfuvirtide. Hepatitis co-infection status was confirmed by hepatitis B surface antigen or HCV antibody and qualitative HCV RNA. Co-infected patients were eligible if they did not require anti-hepatitis treatment and were clinically stable, with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations <5× the upper limit of normal. Adverse events (AEs) and laboratory parameters were analysed. RESULTS: Data were available for 566 etravirine- and 564 placebo-treated patients, of whom 72 (13%) and 68 (12%), respectively, were co-infected with HBV/HCV. Irrespective of co-infection status, the etravirine and placebo groups were comparable for the incidence of grade 3/4 AEs [co-infected: 31 (43%) versus 31 (46%) patients, respectively; non-co-infected: 200 (40%) versus 176 (35%), respectively] and serious AEs [co-infected: 25 (35%) versus 25 (37%), respectively; non-co-infected: 123 (25%) versus 119 (24%), respectively]. Consistent with the underlying hepatitis, relative to non-co-infected patients the co-infected patients, had a higher incidence of hepatic AEs [co-infected: 13 (18%) etravirine-treated versus 10 (15%) placebo-treated patients; non-co-infected: 36 (7%) versus 32 (6%), respectively], and grade 3/4 elevation of AST [co-infected: 8 (11%) versus 5 (7%), respectively; non-co-infected: 14 (3%) versus 9 (2%), respectively] and ALT [co-infected: 10 (14%) versus 6 (9%), respectively; non-co-infected: 14 (3%) versus 8 (2%), respectively]. Discontinuation due to hepatic AEs was low and comparable between the treatment groups, regardless of co-infection status (two co-infected patients in each treatment group; five etravirine-treated versus two placebo-treated non-co-infected patients). CONCLUSIONS: Etravirine demonstrated a similar safety profile to placebo in the subgroup of patients co-infected with HIV and HBV and/or HCV in the DUET trials. The incidence and severity of AEs with etravirine was generally comparable to placebo irrespective of co-infection status.
    [Abstract] [Full Text] [Related] [New Search]